Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Abigail Masters

Nurse Practitioner Kendallville, IN Nurse Practitioner

NPI 1881221893 CMS profile 10923679

326 N Sawyer Rd, Kendallville, IN 46755

Open in the dashboard

General payments

$1,699

99 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Abigail Masters of Kendallville, IN is reported in the CMS Open Payments database as having received $1,699 across 99 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $513 27
2024 General $470 27
2023 General $333 20
2022 General $144 9
2021 General $238 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Abigail Masters
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Abigail Masters were reported at $513. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Abigail Masters Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $238 $135 $40–$426 $132
2022 $144 $152 $48–$470 $149
2023 $333 $166 $54–$529 $160
2024 $470 $173 $55–$556 $164
2025 $513 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $265 14 payments
  2. AbbVie, Inc. $166 11 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $162 10 payments
  4. Novo Nordisk Inc $161 9 payments
  5. Lilly USA, LLC $159 8 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $132 8 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $92 6 payments
  8. GlaxoSmithKline, LLC. $91 6 payments
  9. Sumitomo Pharma America, Inc. $65 3 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $64 4 payments
  11. Other $343 20 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,654 98 payments
  2. Education $45 1 payment
Products named General payments · program years 2021–2025
  1. Kerendia $119 7 payments
  2. RYBELSUS $114 6 payments
  3. Ozempic $114 6 payments
  4. VRAYLAR $105 7 payments
  5. AIRSUPRA $101 5 payments
  6. XIFAXAN $92 6 payments
  7. FARXIGA $86 5 payments
  8. STIOLTO RESPIMAT $83 5 payments
  9. BREZTRI $79 4 payments
  10. TRELEGY ELLIPTA $76 5 payments
  11. Other $1,002 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

1,011

Median for Nurse Practitioner: 389

Drug cost

$65,790

Median for Nurse Practitioner: $21,885

Branded share of claims

23.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 19 $17,393
Januvia Sitagliptin Phosphate Brand 27 $12,110
Ozempic Semaglutide Brand 12 $11,530
Myrbetriq Mirabegron Brand 16 $10,633
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 12 $5,710
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 23 $971
Albuterol Sulfate Hfa Albuterol Sulfate Brand 36 $884
Omeprazole Generic 55 $786
Atorvastatin Calcium Generic 71 $528
Buspirone Hcl Generic 17 $441

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$17,245

Of which drugs: $1,385

Medicare patients

160

Average age 72

Services billed

343

101 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 36%
Ischemic heart disease 30%
COPD 23%
Chronic kidney disease 21%
Depression 18%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 14 14 $1,048

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $78
$78 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $44
$44 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $44
$44 — —
Azstarys
  • Corium, Inc. $37
$37 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record